Our Parkinson's Place: RESEARCHP2Y6 receptor a potential diagnostic biomarker for Parkinson’s disease

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Sunday, March 19, 2017

RESEARCHP2Y6 receptor a potential diagnostic biomarker for Parkinson’s disease

March 13, 2017

Researchers in China have revealed that P2Y6 receptor could be a potential diagnostic biomarker for Parkinson’s disease (PD) and a therapeutic target for treating this neurodegeneration disease.

Parkinson’s disease is a long-term degenerative disorder of the central nervous system (CNS) that is estimated to affect more than 1% of the population aged over 65, and there will be more than 10 million PD patients in the world by 2030. Microglia are involved in immune function within the CNS, and previous studies have associated them with the initiation of neurodegenerative diseases, including PD. The activation of glial cells and increased pro-inflammatory factor levels are common features in PD brains as observed in postmortem analysis of patients.

Nucleotides are known to induce brain inflammation as neurons can release both adenine (such as ATP) and uracil nucleotides (such as UTP and UDP) into the extracellular space upon physiological activity and in response to pathological stimuli and cellular damage, which affects the motility of adjacent cells, including microglia. The ionotropic receptor (P2X) family and the metabotropic receptor (P2Y) family are subfamilies of nucleotide receptors.

The purinoceptor P2Y6 receptor (P2Y6R) is a member of P2Y receptor family and is widely distributed in various tissues including the brain. Damaged neurons are known to release UDP, which binds to P2Y6R and contributes to the microglial phagocytosis of dying neurons.

A study led by Qin Xiao and published in the Journal of Neuroinflammation found that P2Y6R levels were elevated in the peripheral blood mononuclear cells (PBMCs) of PD patients and that UDP/P2Y6R signaling was involved in the neuroinflammation mediated by microglia.

The findings from this study suggested that P2Y6R could be a potential diagnostic biomarker for PD and blocking P2Y6R should be explored as a potential therapeutic strategy for the treatment of PD patients.

https://medicalherald.com/p2y6-receptor-a-potential-diagnostic-biomarker-for-parkinsons-disease/